

Canadian Cardiovascular Society 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
 Panel Member Disclosures
 2022-03-16

The CCS is committed to preserving the scientific integrity of its Guidelines, Clinical Practice Updates and Position Statements through transparency and management of disclosures (industry, academic, financial benefits and other conflicts). Invited and approved panel members must disclose all relationships regardless of relevance to the topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Updated March 8, 2023.

Affiliations with commercial organizations or clinical trials within the previous two years that may have a direct or indirect connection to the content of this statement are disclosed here.

Members	Consulting Fees / Honoraria	Clinical Trials	Other Financial Benefits	Relevance to Statement	
Primary Panel					
Co-Chairs					
First name	Last name				
G. B.	John Mancini	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Janssen, Merck, Novartis, NovoNordisk, Sanofi, Servier, Eisai	Amgen, NovoNordisk	None	Makers or developers of lipid lowering medications. Studies pertain to management of dyslipidemia, metabolic syndrome, diabetes.
Eileen	O'Meara	Astra Zeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Janssen	Amgen, Abbott, American Regent, AstraZeneca, Bayer, Boehringer Ingelheim, Cyclokinetics, Eisai, Novartis, Merck, Sanofi	None	

Panel members					
First name	Last name				
Mathieu	Berner	AstraZeneca, Bayer, Boehringer Ingelheim, Novartis	None	None	Some of these companies make therapies that may be recommended in the guidelines as renal protective therapy.
Alice	Cheng	Abbott Canada, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Decicon, Eisai, Eli Lilly, Janssen, Insulet, NovoNordisk, Sanofi, HLS Therapeutics, Takeda	Applied Therapeutics, Sanofi	None	Some of these trials are in the SGLT2 inhibitor and / or GLP1RA fields.
David	Cherney	Boehringer Ingelheim Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi Tanabe, Abbvie, Janssen, Bayer, Prometheus, MSD, Merck, Glaxo, CSL Behring, Eisai, Novartis, Youngene and Novo-Nordisk	Boehringer Ingelheim Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL Behring and Novo-Nordisk	None	Some of these trials are in the SGLT2 inhibitor and / or GLP1RA fields.
Kim	Connelly	Abbott Canada, AstraZeneca, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Janssen, Merck, NovoNordisk, Sanofi, Servier	AstraZeneca, Boehringer Ingelheim, Novartis, NovoNordisk, Servier	None	
Justin	Esakowitz	Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Merck, Novartis, Servier	American Regent, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Bristol-Myers Squibb, CHS, Merck, Novartis, Pfizer, Sanofi, Tereva	None	I have COI related to diabetes/HF meds (designing and running trials that include these medications).
Ronald M.	Goldenberg	Amgen, AstraZeneca, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, Janssen, Merck, NovoNordisk, Sanofi	AstraZeneca, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, Janssen, Merck, NovoNordisk, Sanofi	None	I have received fees from companies that market drugs for T2D with cardiovascular benefits. I have been a paid investigator for research studies with drugs that have cardiovascular benefits.
Lawrence	Lalor	Abbott Canada, Amgen, AstraZeneca, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, Janssen, Merck, Novartis, NovoNordisk, Sanofi, Servier, HLS	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, GlaxoSmithKline, Janssen, NovoNordisk, Sanofi, Kowa, The Medicines Company	None	These companies make drugs that may be discussed as part of the Guidelines
Gihad	Nesraiah	Baxter Healthcare, ColiGh Care Inc, Advisory boards: Amgen, Bayer, AstraZeneca, GSK	Bayer, Astra-Zeneca	Unrestricted research grant Baxter Healthcare	No relationship to guideline
Breay	Paty	None	Vertex Pharmaceuticals	None	N/A
Marie-Eve	Piché	None	None	None	
Peter	Senior	Bayer, Insulet, Novo Nordisk, Vertex, Viatec	NovoNordisk, Vertex, Viatec	Diabetes Canada Board of Directors	Local PI for several Novo trials using insulin molecules and GLP-1A (all funds to my institution). National Expert Panel for FLOW trial (no financial reimbursement). Chair the Diabetes Canada CPG and will work to ensure alignment between guidelines. It may be helpful (and possibly important) for me to declare a "convergence of interest" as chair for the Diabetes Canada CPG. + I think that this will help ensure alignment and harmonization, but has the potential to represent a conflict of commitment - in which case my commitment to Diabetes Canada would have to take priority. + I would also be required (respecting necessary confidentiality) to keep the DC CPG steering committee informed of activity and progress of this work
Ashvini	Sharma	BMS Pfizer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Eli Lilly, Medtronic, Merck, Novartis, Roche, Takeda, Servier, NovoNordisk, AstraZeneca, Janssen	Boehringer Ingelheim, Sanofi, Merck	COO of D3 health and stocks in Pillow health	Several companies develop and market molecules relating to glucose lowering drugs. Several companies are currently testing molecules relating to glucose lowering drugs.
Subodh	Verma	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge Transition Research Group, Eli Lilly, HLS Therapeutics, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Phasello, Sanofi, S & L Solutions Event Management Inc	Amaris, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Janssen, Merck, Novo Nordisk, Pfizer, Phasello	None	N/A
Vincent	Woo	AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, NovoNordisk	AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, NovoNordisk	None	none, accredited slide kits used for speaking, renal outcomes were assessed in the SGLT2 inhibitor studies.
Shelley	Zieroth	Abbot, Alkerm, Amgen, AstraZeneca, Boehringer Ingelheim, Cardo Therapeutics, Novartis, Pfizer, Servier	Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Merck, Novartis	None	

Secondary Panel					
First name	Last name				
Pol	Darras	None	None	None	
Jonathan	Gabor	Amgen, AstraZeneca, Bayer, BMS-Pfizer, Boehringer-Ingelheim / Eli Lilly Alliance, HLS Therapeutics, Janssen, Novartis, NovoNordisk, Pfizer, Servier	None	None	Speaking fees and/or Advisory Board. Some of the companies in the COI disclosure market drugs for cardiovascular disease.
Neil	Grigore	Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim / Eli Lilly Alliance, Bristol Myers Squibb, Janssen, Merck, Novartis, NovoNordisk, Pfizer, Sanofi, Servier	None	None	No relationship to guideline
Eva	Linn	Amgen, HLS Therapeutics, Novartis, Servier, UB Therapeutics, NovoNordisk	Amgen, Bayer, Boehringer Ingelheim, Merck, Roche	None	No relationship to guideline
James	Stone	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim / Eli Lilly Alliance, NovoNordisk, Sanofi, Servier	None	None	Lipid modifying products
Jean-Francois	Vale	Abbott Canada, AstraZeneca, Bayer, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, Janssen, Medtronic, Merck, Novartis, NovoNordisk, Sanofi	AstraZeneca, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, Janssen, Medtronic, NovoNordisk, Sanofi	None	I give lectures and participate in advisory boards. Most companies do agents that may be discussed in the guidelines. Participated in numerous cardiovascular trials that may be discussed in these guidelines.
Colin	Young	None	None	None	N/A
Deborah	Zimmerman	Osuka	None	None	No relationship to guideline